Announcement no. 17
Interim Results
For the third quarter ending
- Total revenue of
DKK 8.6 million /USD 1.3 million , a 63% increase over the prior year - Adjusted EBITDA of
DKK (9.7) million /USD (1.4) million
For the nine months ending
- Total revenue of
DKK 24,4 million /USD 3.5 million , a 20% increase over the prior year - Adjusted EBITDA of
DKK (41.2) million /USD (6.0) million - Cash and cash equivalents of
DKK 69.9 million /USD 9.9 million as ofSeptember 30, 2023 (DKK 98.9 million /USD 13.0 million as ofSeptember 30, 2022 )
Guidance for 2023 revised
With due regard to the results obtained in the first nine months of 2023,
- Revenue of approximately
DKK 30 to 33 million (unchanged), and - Adjusted EBITDA loss of approximately
DKK (56) to (59) million (previouslyDKK (60) to (65) million)
The adjusted EBITDA is based on the Company’s focused expense control during the FDA review period.
BioPorto’s full disclosure of the financial results for the first nine months of 2023 will be published on 1.
Conference Call and Webcast
The Company’s management team will host an online investor presentation on
https://hca.videosync.fi/2023-10-11-bioporto-q3/register.
A separate analyst call will be held on
International: +1 201 689 8562
US: +1 877 407 0789
Conference ID: 13739662
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1640499&tp_key=67270c5bab
Operator assisted dial-out:
https://callme.viavid.com/viavid/?callme=true&passcode=13732188&h=true&info=company-email&r=true&B=6
Investor Relations Contacts
About
The Company’s flagship product is The NGAL TestTM, which has been designed to aid in the risk assessment of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in a number of countries worldwide.
Forward-looking statement disclaimer
Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company’s expectations, intentions and projections regarding its future performance including the Company’s Guidance for 2023; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to the potential FDA marketing authorization, implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company’s ability to successfully market both new and existing products. These forward-looking statements, which may use words such as “aim”, “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company’s business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto’s success are more fully disclosed in BioPorto’s periodic financial filings with the
Attachment
- 2023 10 31 - Announcement no. 17
© OMX, source